Gilead Sciences Inc. (NASDAQ:GILD) shares traded up 1.8% during mid-day trading on Friday . The stock traded as high as $87.96 and last traded at $87.07, with a volume of 7,670,166 shares. The stock had previously closed at $85.54.

Several research analysts have recently issued reports on the stock. Jefferies Group restated a “hold” rating and issued a $97.00 target price on shares of Gilead Sciences in a report on Friday. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $97.00 price target for the company in a research note on Monday. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Sunday, July 10th. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $95.02 price target for the company. in a research note on Wednesday, July 6th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Gilead Sciences in a research note on Tuesday, July 5th. Eight investment analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $114.05.

The stock has a market cap of $115.43 billion and a price-to-earnings ratio of 7.40. The firm has a 50-day moving average of $84.56 and a 200 day moving average of $89.56.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported $3.03 earnings per share for the quarter, missing the consensus estimate of $3.13 by $0.10. The business had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $8.08 billion. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $2.94 EPS. On average, equities research analysts predict that Gilead Sciences Inc. will post $12.06 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, June 29th. Shareholders of record on Thursday, June 16th were given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.17%. The ex-dividend date was Tuesday, June 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.43.

In other Gilead Sciences news, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, April 19th. The shares were sold at an average price of $100.01, for a total transaction of $4,000,400.00. Following the transaction, the executive vice president now directly owns 177,964 shares in the company, valued at approximately $17,798,179.64. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO John F. Milligan sold 112,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, May 2nd. The stock was sold at an average price of $87.71, for a total transaction of $9,823,520.00. Following the transaction, the chief executive officer now owns 1,170,963 shares in the company, valued at $102,705,164.73. The disclosure for this sale can be found here.

A number of institutional investors have recently bought and sold shares of GILD. Gabelli Funds LLC boosted its position in Gilead Sciences by 6.0% in the fourth quarter. Gabelli Funds LLC now owns 177,000 shares of the biopharmaceutical company’s stock valued at $17,911,000 after buying an additional 10,000 shares during the last quarter. Shelton Capital Management boosted its position in Gilead Sciences by 4.7% in the fourth quarter. Shelton Capital Management now owns 142,218 shares of the biopharmaceutical company’s stock valued at $14,391,000 after buying an additional 6,370 shares during the last quarter. Callahan Advisors LLC boosted its position in Gilead Sciences by 5.2% in the fourth quarter. Callahan Advisors LLC now owns 85,492 shares of the biopharmaceutical company’s stock valued at $8,651,000 after buying an additional 4,229 shares during the last quarter. Mayo Investment Advisers LLC boosted its position in Gilead Sciences by 12.3% in the fourth quarter. Mayo Investment Advisers LLC now owns 68,900 shares of the biopharmaceutical company’s stock valued at $6,972,000 after buying an additional 7,550 shares during the last quarter. Finally, YHB Investment Advisors Inc. boosted its position in Gilead Sciences by 15.7% in the fourth quarter. YHB Investment Advisors Inc. now owns 49,114 shares of the biopharmaceutical company’s stock valued at $4,970,000 after buying an additional 6,666 shares during the last quarter.

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.